190
Views
9
CrossRef citations to date
0
Altmetric
Reviews

Regulation of collagen-derived antiangiogenic factors by p53

, MSc & , PhD
Pages 941-950 | Published online: 12 Jun 2008

Bibliography

  • Gabellini C, Del Bufalo D, Zupi G. Involvement of RB gene family in tumor angiogenesis. Oncogene 2006;25:5326-32
  • Kondo K, Kaelin WG Jr. The von Hippel-Lindau tumor suppressor gene. Exp Cell Res 2001;264:117-25
  • Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53
  • Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10
  • Momand J, Wu HH, Dasgupta G. MDM2–master regulator of the p53 tumor suppressor protein. Gene 2000;242:15-29
  • Carr AM. Cell cycle. Piecing together the p53 puzzle. Science 2000;287:1765-6
  • Sherr CJ, Weber JD. The ARF/p53 pathway. Curr Opin Genet Dev 2000;10:94-9
  • Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31
  • Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992;70:523-6
  • Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002;2:594-604
  • Holmgren L, Jackson G, Arbiser J. p53 induces angiogenesis-restricted dormancy in a mouse fibrosarcoma. Oncogene 1998;17:819-24
  • Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev 2000;14:34-44
  • Zhang L, Yu D, Hu M, et al. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res 2000;60:3655-61
  • Sherif ZA, Nakai S, Pirollo KF, et al. Downmodulation of bFGF-binding protein expression following restoration of p53 function. Cancer Gene Ther 2001;8:771-82
  • Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994;265:1582-4
  • Teodoro JG, Evans SK, Green MR. Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J Mol Med 2007;85:1175-86
  • Teodoro JG, Parker AE, Zhu X, Green MR. p53-mediated inhibition of angiogenesis through up-regulation of a collagen prolyl hydroxylase. Science 2006;313:968-71
  • Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 2003;3:422-33
  • Prockop DJ, Kivirikko KI. Collagens: molecular biology, diseases, and potentials for therapy. Ann Rev Biochem 1995;64:403-34
  • Nissi R, Autio-Harmainen H, Marttila P, et al. Prolyl 4-hydroxylase isoenzymes I and II have different expression patterns in several human tissues. J Histochem Cytochem 2001;49:1143-53
  • Paulsson M. Basement membrane proteins: structure, assembly, and cellular interactions. Crit Rev Biochem Mol Biol 1992;27:93-127
  • Colorado PC, Torre A, Kamphaus G, et al. Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res 2000;60:2520-6
  • Pozzi A, Wary KK, Giancotti FG, Gardner HA. Integrin α1β1 mediates a unique collagen-dependent proliferation pathway in vivo. J Cell Biol 1998;142:587-94
  • Bloch W, Forsberg E, Lentini S, et al. β1 integrin is essential for teratoma growth and angiogenesis. J Cell Biol 1997;139:265-78
  • Kamphaus GD, Colorado PC, Panka DJ, et al. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem 2000;275:1209-15
  • Petitclerc E, Boutaud A, Prestayko A, et al. New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo. J Biol Chem 2000;275:8051-61
  • Magnon C, Galaup A, Mullan B, et al. Canstatin acts on endothelial and tumor cells via mitochondrial damage initiated through interaction with αvβ3 and αvβ5 integrins. Cancer Res 2005;65:4353-61
  • Panka DJ, Mier JW. Canstatin inhibits Akt activation and induces Fas-dependent apoptosis in endothelial cells. J Biol Chem 2003;278:37632-6
  • Maeshima Y, Colorado PC, Torre A, et al. Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem 2000;275:21340-8
  • Maeshima Y, Yerramalla UL, Dhanabal M, et al. Extracellular matrix-derived peptide binds to α(v)β(3) integrin and inhibits angiogenesis. J Biol Chem 2001;276:31959-68
  • Maeshima Y, Sudhakar A, Lively JC, et al. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 2002;295:140-3
  • Han J, Ohno N, Pasco S, et al. A cell binding domain from the α3 chain of type IV collagen inhibits proliferation of melanoma cells. J Biol Chem 1997;272:20395-401
  • Maeshima Y, Colorado PC, Kalluri R. Two RGD-independent αvβ3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J Biol Chem 2000;275:23745-50
  • Pasco S, Ramont L, Maquart FX, Monboisse JC. Control of melanoma progression by various matrikines from basement membrane macromolecules. Crit Rev Oncol Hematol 2004;49:221-33
  • Shahan TA, Ziaie Z, Pasco S, et al. Identification of CD47/integrin-associated protein and α(v)β3 as two receptors for the α3(IV) chain of type IV collagen on tumor cells. Cancer Res 1999;59:4584-90
  • Kawaguchi T, Yamashita Y, Kanamori M, et al. The PTEN/Akt pathway dictates the direct αVβ3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo. Cancer Res 2006;66:11331-40
  • McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for matrix anymore. Curr Opin Cell Biol 2001;13:534-40
  • Hamano Y, Zeisberg M, Sugimoto H, et al. Physiological levels of tumstatin, a fragment of collagen IV α3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via αVβ3 integrin. Cancer Cell 2003;3:589-601
  • O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85
  • Wen W, Moses MA, Wiederschain D, et al. The generation of endostatin is mediated by elastase. Cancer Res 1999;59:6052-6
  • Felbor U, Dreier L, Bryant RA, et al. Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J 2000;19:1187-94
  • Sasaki T, Hohenester E, Timpl R. Structure and function of collagen-derived endostatin inhibitors of angiogenesis. IUBMB Life 2002;53:77-84
  • Dixelius J, Cross M, Matsumoto T, et al. Endostatin regulates endothelial cell adhesion and cytoskeletal organization. Cancer Res 2002;62:1944-7
  • Dhanabal M, Volk R, Ramchandran R, et al. Cloning, expression, and in vitro activity of human endostatin. Biochem Biophys Res Commun 1999;258:345-52
  • Sudhakar A, Sugimoto H, Yang C, et al. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by αvβ3 and α5β1 integrins. Proc Natl Acad Sci USA 2003;100:4766-71
  • Kim YM, Hwang S, Kim YM, et al. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem 2002;277:27872-9
  • Abdollahi A, Hahnfeldt P, Maercker C, et al. Endostatin's antiangiogenic signaling network. Mol Cell 2004;13:649-63
  • Shi H, Huang Y, Zhou H, et al. Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin. Blood 2007;110:2899-906
  • Srivastava M, Pollard HB. Molecular dissection of nucleolin's role in growth and cell proliferation: new insights. FASEB J 1999;13:1911-22
  • Kim YM, Jang JW, Lee OH, et al. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res 2000;60:5410-3
  • Lee SJ, Jang JW, Kim YM, et al. Endostatin binds to the catalytic domain of matrix metalloproteinase-2. FEBS Lett 2002;519:147-52
  • Nyberg P, Heikkila P, Sorsa T, et al. Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation of matrix metalloprotease-2, -9, and -13. J Biol Chem 2003;278:22404-11
  • Ramchandran R, Dhanabal M, Volk R, et al. Antiangiogenic activity of restin, NC10 domain of human collagen XV: comparison to endostatin. Biochem Biophys Res Commun 1999;255:735-9
  • Sasaki T, Larsson H, Tisi D, et al. Endostatins derived from collagens XV and XVIII differ in structural and binding properties, tissue distribution and anti-angiogenic activity. J Mol Biol 2000;301:1179-90
  • Miled C, Pontoglio M, Garbay S, et al. A genomic map of p53 binding sites identifies novel p53 targets involved in an apoptotic network. Cancer Res 2005;65:5096-104
  • Wei CL, Wu Q, Vega VB, et al. A global map of p53 transcription-factor binding sites in the human genome. Cell 2006;124:207-19
  • Form DM, Pratt BM, Madri JA. Endothelial cell proliferation during angiogenesis. In vitro modulation by basement membrane components. Lab Invest 1986;55:521-30
  • Herbst TJ, McCarthy JB, Tsilibary EC, Furcht LT. Differential effects of laminin, intact type IV collagen, and specific domains of type IV collagen on endothelial cell adhesion and migration. J Cell Biol 1988;106:1365-73
  • Furcht LT. Role of cell adhesion molecules in promoting migration of normal and malignant cells. Prog Clin Biol Res 1984;149:15-53
  • Ingber D, Folkman J. Inhibition of angiogenesis through modulation of collagen metabolism. Lab Invest 1988;59:44-51
  • Haralabopoulos GC, Grant DS, Kleinman HK, et al. Inhibitors of basement membrane collagen synthesis prevent endothelial cell alignment in matrigel in vitro and angiogenesis in vivo. Lab Invest 1994;71:575-82
  • Maragoudakis ME, Haralabopoulos GC, Tsopanoglou NE, Pipili-Synetos E. Validation of collagenous protein synthesis as an index for angiogenesis with the use of morphological methods. Microvasc Res 1995;50:215-22
  • Maragoudakis ME, Missirlis E, Karakiulakis GD, et al. Basement membrane biosynthesis as a target for developing inhibitors of angiogenesis with anti-tumor properties. Kidney Int 1993;43:147-50
  • Oberbaumer I, Wiedemann H, Timpl R, Kuhn K. Shape and assembly of type IV procollagen obtained from cell culture. Embo J 1982;1:805-10
  • Grant DS, Kibbey MC, Kinsella JL, et al. The role of basement membrane in angiogenesis and tumor growth. Pathol Res Pract 1994;190:854-63
  • Bian J, Sun Y. Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. Mol Cell Biol 1997;17:6330-8
  • Flannery CR. MMPs and ADAMTSs: functional studies. Front Biosci 2006;11:544-69
  • Yang Q, Rasmussen SA, Friedman JM. Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet 2002;359:1019-25
  • Folkman J, Kalluri R. Cancer without disease. Nature 2004;427:787
  • Zorick TS, Mustacchi Z, Bando SY, et al. High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours. Eur J Hum Genet 2001;9:811-4
  • Sund M, Hamano Y, Sugimoto H, et al. Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc Natl Acad Sci USA 2005;102:2934-9
  • Black WC, Welch HG. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N Engl J Med 1993;328:1237-43
  • Harach HR, Franssila KO, Wasenius VM. Occult papillary carcinoma of the thyroid. A “normal” finding in Finland. A systematic autopsy study. Cancer 1985;56:531-8
  • Nielsen M, Thomsen JL, Primdahl S, et al. Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies. Br J Cancer 1987;56:814-9
  • Folkman J, Long DM Jr, Becker FF. Growth and metastasis of tumor in organ culture. Cancer 1963;16:453-67
  • Gautam A, Densmore CL, Melton S, et al. Aerosol delivery of PEI-p53 complexes inhibits B16-F10 lung metastases through regulation of angiogenesis. Cancer Gene Ther 2002;9:28-36
  • Kaminski JM, Shinohara E, Summers JB, et al. The controversial abscopal effect. Cancer Treat Rev 2005;31:159-72
  • Camphausen K, Moses MA, Menard C, et al. Radiation abscopal antitumor effect is mediated through p53. Cancer Res 2003;63:1990-3
  • Hartford AC, Gohongi T, Fukumura D, Jain RK. Irradiation of a primary tumor, unlike surgical removal, enhances angiogenesis suppression at a distal site: potential role of host-tumor interaction. Cancer Res 2000;60:2128-31
  • O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28
  • Sckell A, Safabakhsh N, Dellian M, Jain RK. Primary tumor size-dependent inhibition of angiogenesis at a secondary site: an intravital microscopic study in mice. Cancer Res 1998;58:5866-9
  • Prehn RT. The inhibition of tumor growth by tumor mass. Cancer Res 1991;51:2-4
  • Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007;6:273-86
  • Yu JL, Rak JW, Coomber BL, et al. Effect of p53 status on tumor response to antiangiogenic therapy. Science 2002;295:1526-8
  • Giuriato S, Ryeom S, Fan AC, et al. Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proc Natl Acad Sci USA 2006;103:16266-71
  • Roy R, Wewer UM, Zurakowski D, Pories SE, Moses MA. ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J Biol Chem 2004;279:51323-30

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.